Utama › Kanser Prostat › California › Orange
Kajian klinikal Kanser Prostat di Orange, CA
14 kajian untuk Kanser Prostat sedang mencari peserta di lokasi dalam dan sekitar Orange (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Mengambil pesertaFasa 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Mengambil pesertaFasa 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Mengambil pesertaFasa 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Mengambil pesertaFasa 3
- University of California Irvine, Orange
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Mengambil pesertaFasa 3
- Univ Cali Irvine ALS Neuromuscular, Orange
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Mengambil pesertaFasa 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0006), Orange
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Mengambil pesertaFasa 3
- UC Irvine Health, Orange
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Mengambil pesertaFasa 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Mengambil pesertaFasa 1
- UCI Health Chao Family Comprehensive Cancer Center, Orange
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Mengambil pesertaFasa 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Mengambil pesertaFasa 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Mengambil pesertaFasa 1/2
- UC Irvine Medical Center, Orange
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Mengambil pesertaFasa 4
- St. Joseph Hospital, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Orange
Kajian Kanser Prostat di bandar lain
- New York City, NY103 kajian
- Houston, TX76 kajian
- Los Angeles, CA61 kajian
- Boston, MA59 kajian
- St. Louis, MO46 kajian
- Chicago, IL45 kajian
- San Francisco, CA45 kajian
- Philadelphia, PA44 kajian
- Baltimore, MD43 kajian
- Nashville, TN42 kajian
- Seattle, WA42 kajian
- Washington, DC38 kajian
Kajian lain di Orange
- Kanser Paru-paru Bukan Sel Kecil25 kajian
- Kanser Metastatik20 kajian
- Kanser Kolorektal16 kajian
- Kanser Ovari16 kajian
- Kanser Pankreas15 kajian
- Kanser Payudara14 kajian
- Kanser Paru-paru14 kajian
- Kanser Hati (Karsinoma Hepatoselular)14 kajian
- Melanoma14 kajian
- Leukemia Mieloid Akut13 kajian
- Kanser (semua jenis)13 kajian
- Kanser Perut13 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.